Quantcast
Breast Cancer Drug Perjeta Shows Unprecedented Success In

Breast Cancer Drug Perjeta Shows 'Unprecedented' Success In Clinical Trials

Chuck Bednar for redOrbit.com - Your Universe Online Perjeta, a new breast cancer drug developed by Swiss pharmaceutical company Roche, has shown “unprecedented” success in extending the lives of patients in a clinical trial, according to...

Latest metastatic breast cancer Stories

2014-09-23 08:30:28

#MBCStrength Encourages Women Living with Metastatic Breast Cancer to Share their Strength and Inspiration with Others WILMINGTON, Del., Sept. 23, 2014 /PRNewswire/ -- More than 173,000 women in the United States are living with metastatic breast cancer and each has a story to tell. AstraZeneca is launching a nationwide photo-sharing campaign to provide them another way to share their inspiration, experiences and strengths with others. To view the multimedia assets associated with...

2014-09-17 04:20:02

Tokyo, Sept 17, 2014 - (JCN Newswire) - Eisai Co., Ltd. announced today that a series of abstracts highlighting the latest clinical data on Halaven(R) (generic name: eribulin mesylate; non-taxane microtubule dynamics inhibitor, "Halaven") and lenvatinib mesylate (generic name; selective inhibitor of receptor tyrosine kinases (RTKs) with a novel binding mode, "lenvatinib") will be presented during the 39th European Society for Medical Oncology (ESMO) Congress...

2014-08-19 16:29:12

GILBERT, Ariz., Aug. 19, 2014 /PRNewswire/ -- A cutting-edge research study at Banner MD Anderson Cancer Center is testing the safety and effectiveness of a new investigational drug that, when combined with chemotherapy, may make a major difference in treating breast cancer in patients who carry harmful mutations on either the BRCA1 or BRCA2 genes. The Brocade Study will enroll patients with hereditary breast cancer that is metastatic, meaning it has spread to other parts of the...

2014-08-04 23:05:39

MarketReportsOnline.com adds "Global Breast Cancer Market Report: 2014 Edition" report to its research store. Dallas, Texas (PRWEB) August 04, 2014 The most common risk factor for breast cancer is being female and growing older. White women are slightly more probable to get breast cancer than African-American women. African-American women, though, are more likely to die of breast cancer. Although men are diagnosed at a much smaller rate than women, their chances of being...

2014-07-30 08:33:06

Studies Support Ongoing Clinical Strategy of Using Syndax's Entinostat as Epigenetic Priming to Immune Therapy WALTHAM, Mass., July 30, 2014 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. today announced that newly published results demonstrate that in preclinical studies entinostat significantly improved treatment outcomes in mouse tumor models when combined with anti-PD1 and anti-CTLA4 targeted antibodies. The paper from Kim, et al. at The Sidney Kimmel Comprehensive Cancer Center,...

2014-07-10 12:19:38

Rockefeller University Unexpected links to Alzheimer's disease and Huntington's disease also seen Using an innovative tool that captures heretofore hidden ways that cells are regulated, scientists at Rockefeller University have identified a protein that makes breast cancer cells more likely to metastasize. What's more, the protein appears to trigger cancer's spread in part by blocking two other proteins that are normally linked to neurodegeneration, a finding that suggests these two...

2014-07-03 20:20:02

Tokyo, July 3, 2014 - (JCN Newswire) - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that it has received approval from the European Commission of the indication expansion of Halaven (generic name: eribulin mesylate, "eribulin") to contribute to earlier treatment of patients with locally advanced or metastatic breast cancer who have progressed after at least one chemotherapeutic regimen for advanced disease. Prior therapy should...

2014-07-02 10:59:23

Cornell University Every living cell's surface has a protein-embedded membrane that's covered in polysaccharide chains – a literal sugar coating. A new study by a Cornell University researcher found this coating is especially thick and pronounced on cancer cells and is a crucial determinant of the cell's survival. Consisting of long, sugar-decorated molecules called glycoproteins, the coating causes physical changes in the cell membrane that make the cell better able to thrive –...

2014-06-24 14:00:24

NYU Langone Medical Center / New York University School of Medicine Leading experts from renowned academic centers join in one voice to encourage new perspectives in addressing brain cancer A blue-ribbon team of national experts on brain cancer says that professional pessimism and out-of-date "myths," rather than current science, are guiding -- and compromising -- the care of patients with cancers that spread to the brain. In a special article published in the July issue of...

2014-06-04 15:45:13

Cornell University Not all cancer cells are created equal – some stay put in the primary tumor, while others move and invade elsewhere. A major goal for cancer research is predicting which cells will metastasize, and why. A Cornell cancer research team is taking a new approach to screening for these dangerous cells, using a microfluidic device they invented that isolates only the most aggressive, metastatic cells. “The approach we’ve taken is a reverse approach from what is...


Word of the Day
humgruffin
  • A terrible or repulsive person.
Regarding the etymology of 'humgruffin,' the OED says (rather unhelpfully) that it's a 'made-up word.' We might guess that 'hum' comes from 'humbug' or possibly 'hum' meaning 'a disagreeable smell,' while 'gruffin' could be a combination of 'gruff' and 'griffin.'